![]() ![]() In summary, because we concluded that extended-release niacin provided no benefit, and because of possible safety concerns, the study was stopped 18 months earlier than planned. The apparent increase in the risk of stroke has not been seen in previous niacin studies investigators are now analyzing the data. The number of participants who experienced serious heart and vascular events was about the same in people who received extended release niacin as in those who received an inactive pill (placebo) instead.Īlthough more participants on extended release niacin experienced strokes than did those on placebo, the risk of a stroke among trial participants in either of the two groups was small - less than 1 percent per year. We are stopping the AIM-HIGH trial early because we found no evidence that adding extended release niacin prevents these complications, even though it was effective at raising HDL cholesterol. The goal of the AIM-HIGH trial was to learn whether raising HDL (“good”) cholesterol with extended release niacin decreases the risk of heart attack, stroke, and other heart-related complications to a greater extent than with statins alone. ![]() We are stopping the AIM-HIGH trial because there is little to no chance that the trial will ever show a benefit of extended release niacin in patients similar to you. We are writing you as a valued participant in the AIM-HIGH study to share important news before an announcement is made to the general public and news media on Thursday, May 26, 2011. Dear participant in the “AIM-HIGH” Trial,
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |